

Juan G. Abraldes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8819036/juan-g-abraldes-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

12,107
citations

58
h-index

109
g-index

148
ext. papers

14,658
ext. citations

6.9
avg, IF

6.24
L-index

#	Paper	IF	Citations
137	Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list.. <i>Hepatology Communications</i> , 2022 ,	6	1
136	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).. <i>Liver International</i> , 2022 ,	7.9	1
135	A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. <i>BMC Gastroenterology</i> , 2021 , 21, 120	3	3
134	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021 , 74, 1660-1673	11.2	20
133	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021 , 75, 1026-1033	13.4	3
132	Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021 , 41, 819-827	7.9	0
131	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021 , 74, 200-219	13.4	8
130	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S118-S134	13.4	7
129	Non-invasive alloimmune risk stratification of long-term liver transplant recipients. <i>Journal of Hepatology</i> , 2021 , 75, 1409-1419	13.4	0
128	Liver cirrhosis. <i>Lancet, The</i> , 2021 , 398, 1359-1376	40	50
127	Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?. <i>Journal of Hepatology</i> , 2021 , 75, 750-752	13.4	1
126	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.. <i>Hepatology Communications</i> , 2021 ,	6	1
125	Can We Add the History of the Nonoperative Therapy of Varices to Other Success Chapters of Modern Medicine?. <i>Clinical Liver Disease</i> , 2020 , 16, 73-82	2.2	1
124	Cirrhosis as new indication for statins. <i>Gut</i> , 2020 , 69, 953-962	19.2	32
123	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020 , 72, 1353-1365	11.2	14
122	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020 , 73, 1082-1091	13.4	52
121	Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. <i>Hepatology</i> , 2020 , 72, 1029-1042	11.2	7

120	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 31-41	18.8	43
119	Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. <i>Liver International</i> , 2019 , 39, 1271-1280	7.9	15
118	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019 , 393, 1597-1608	40	160
117	Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. <i>Liver International</i> , 2019 , 39, 1437-1447	7.9	47
116	Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. <i>Hepatology Communications</i> , 2019 , 3, 1322-1333	6	33
115	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019 , 69, 1287-1299	11.2	28
114	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018 , 154, 1694-1705.e4	13.3	90
113	Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence. <i>Scientific Reports</i> , 2018 , 8, 99	4.9	58
112	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. <i>Journal of Hepatology</i> , 2018 , 69, 626-634	13.4	25
111	The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2018 , 16, 226-240	2.5	19
110	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. <i>Shock</i> , 2017 , 47, 370-377	3.4	21
109	Bacterial infections in acute variceal hemorrhage despite antibiotics-a multicenter study of predictors and clinical impact. <i>United European Gastroenterology Journal</i> , 2017 , 5, 1090-1099	5.3	8
108	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i> , 2017 , 65, 310-335	11.2	936
107	Management of Portal Hypertension 2017 , 304-335		
106	Patient-perceived barriers to lifestyle interventions in cirrhosis. <i>Saudi Journal of Gastroenterology</i> , 2017 , 23, 97-104	3	14
105	Reply. <i>Gastroenterology</i> , 2016 , 151, 1037-1038	13.3	
104	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016 , 150, 1160-1170.e3	13.3	171
103	Statins: the Panacea of Cirrhosis?. <i>Current Hepatology Reports</i> , 2016 , 15, 1-7	1	5

102 Issues in Trial Design and Areas Needing Further Research **2016**, 355-363

101	A Model to Identify Sarcopenia in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1473-1480.e3	6.9	108
100	A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1759-1767	0.7	102
99	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. <i>Liver International</i> , 2015 , 35, 695-703	7.9	14
98	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015 , 64, 1434-43	19.2	115
97	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015 , 62, 762-72	11.2	159
96	A histologic scoring system for prognosis of patients with alcoholic hepatitis. <i>Gastroenterology</i> , 2014 , 146, 1231-9.e1-6	13.3	254
95	Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1920-6.e2	6.9	131
94	Lack of correlation between preoperative and intraoperative liver hemodynamics: a descriptive analysis. <i>Transplantation</i> , 2014 , 97, 116-21	1.8	2
93	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014 , 34, 16-25	7.9	38
92	A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. <i>Gastroenterology</i> , 2014 , 146, 412-19.e3	13.3	183
91	Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013 , 58, 45-50	13.4	209
90	Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. <i>Gastroenterology & Hepatology</i> , 2013 , 36, 527-33	0.9	17
89	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. <i>Journal of Hepatology</i> , 2013 , 58, 1140-6	13.4	47
88	Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. <i>Gastroenterology</i> , 2013 , 144, 102-111.e1	13.3	336
87	Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension. <i>American Journal of Gastroenterology</i> , 2013 , 108, 926-32	0.7	21
86	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013 , 57, 1172-81	11.2	66
85	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2013 , 59, 717-22	13.4	16

84	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. <i>Hepatology</i> , 2013 , 57, 1962-8	11.2	180
83	Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. <i>Hepatology</i> , 2013 , 58, 1824-35	11.2	203
82	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 305, G496-502	5.1	15
81	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. <i>Liver Transplantation</i> , 2013 , 19, 450-6	4.5	7
80	Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. <i>American Journal of Gastroenterology</i> , 2013 , 108, 75-82	0.7	20
79	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013 , 58, 2079-88	11.2	33
78	Spleen stiffness: toward a noninvasive portal sphygmomanometer?. <i>Hepatology</i> , 2013 , 57, 1278-80	11.2	21
77	Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. <i>PLoS ONE</i> , 2013 , 8, e58742	3.7	92
76	Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1125-33	5.6	28
75	Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 72-8	6.9	29
74	Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 776-83	6.9	336
73	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012 , 56, 103-8	13.4	114
72	Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 2017-21	5.6	
71	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. <i>Digestive and Liver Disease</i> , 2012 , 44, 855-60	3.3	85
70	Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. <i>Gastroenterología Y Hepatología</i> , 2012 , 35, 488-95	0.9	27
69	Patients whose first episode of bleeding occurs while taking a Bblocker have high long-term risks of rebleeding and death. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 670-6; quiz e58	6.9	23
68	Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. <i>PLoS ONE</i> , 2012 , 7, e32785	3.7	136
67	Insulin resistance in patients with cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, G1458-65	5.1	18

66	Acute variceal bleeding. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 46-54	3.9	53
65	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 584-90	7	43
64	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. <i>Journal of Clinical Investigation</i> , 2012 , 122, 368-82	15.9	150
63	Complications after ERCP in liver transplant recipients. <i>Gastrointestinal Endoscopy</i> , 2011 , 74, 285-94	5.2	31
62	The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1472-80	0.7	25
61	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. <i>Journal of Hepatology</i> , 2011 , 55, 307-14	13.4	36
60	Insulin resistance and liver microcirculation in a rat model of early NAFLD. <i>Journal of Hepatology</i> , 2011 , 55, 1095-102	13.4	54
59	Portal cholangiopathy: radiological classification and natural history. <i>Gut</i> , 2011 , 60, 853-60	19.2	65
58	Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. <i>Gut</i> , 2011 , 60, 1133-8	19.2	102
57	Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. <i>Disease Markers</i> , 2011 , 31, 129-38	3.2	22
56	Characterization of T cell subsets in organ transplantation. <i>Transplant International</i> , 2010 , 23, 1045-55	3	54
55	Early use of TIPS in patients with cirrhosis and variceal bleeding. <i>New England Journal of Medicine</i> , 2010 , 362, 2370-9	59.2	802
54	Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders. <i>World Journal of Gastroenterology</i> , 2010 , 16, 6123-7	5.6	23
53	A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1917-21	0.7	11
52	Developments and controversies in the management of oesophageal and gastric varices. <i>Gut</i> , 2010 , 59, 701-5	19.2	15
51	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. <i>Journal of Hepatology</i> , 2010 , 52, 846-53	13.4	90
50	Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2010 , 53, 273-82	13.4	85
49	Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2010 , 53, 558-67	13.4	132

48	An uncommon cause of massive scrotal enlargement. <i>Liver International</i> , 2010 , 30, 995	7.9	
47	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. <i>Hepatology</i> , 2010 , 51, 2108-16	11.2	57
46	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010 , 52, 1783-90	11.2	70
45	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2010 , 52, 2044-52	11.2	143
44	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. <i>Liver Transplantation</i> , 2010 , 16, 348-56	4.5	58
43	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2009 , 51, 279-87	13.4	101
42	Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. <i>Gastroenterology</i> , 2009 , 136, 1651-8	13.3	288
41	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009 , 6, 573-82	24.2	441
40	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 296, G147-56	5.1	65
39	Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. <i>Liver International</i> , 2008 , 28, 566-73	7.9	6
38	A new scoring system for prognostic stratification of patients with alcoholic hepatitis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2747-56	0.7	200
37	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008 , 48, 229-36	13.4	231
36	Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1412-7	6.9	142
35	Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1159-67	0.7	103
34	Portal hypertension and gastrointestinal bleeding. <i>Seminars in Liver Disease</i> , 2008 , 28, 3-25	7.3	86
33	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008 , 48, 442-8	11.2	292
32	The management of portal hypertension: rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008 , 48 Suppl 1, S68-92	13.4	191
31	Decreased intrahepatic response to alpha(1)-adrenergic agonists in lipopolysaccharide-treated rats is located in the sinusoidal area and depends on Kupffer cell function. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 893-900	4	5

30	The treatment of acute variceal bleeding. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41 Suppl 3, S312-7	3	39
29	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCL4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007 , 46, 1040-6	13.4	169
28	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. <i>Hepatology</i> , 2006 , 43, 27-33	11.2	33
27	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006 , 43, 34-41	11.2	26
26	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006 , 43, 485-91	11.2	93
25	Measurement of portal pressure and its role in the management of chronic liver disease. <i>Seminars in Liver Disease</i> , 2006 , 26, 348-62	7.3	160
24	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G980-7	5.1	138
23	Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2006 , 44, 1040-5	13.4	6
22	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2006 , 44, 886-93	13.4	39
21	Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. <i>American Journal of Gastroenterology</i> , 2006 , 101, 506-12	0.7	200
20	Variceal bleeding: pharmacological therapy. <i>Digestive Diseases</i> , 2005 , 23, 18-29	3.2	17
19	Portal hypertension secondary to myelofibrosis: a study of three cases. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2355-8	0.7	26
18	The management of portal hypertension. <i>Clinics in Liver Disease</i> , 2005 , 9, 685-713, vii	4.6	23
17	Portal hypertension: from bedside to bench. <i>Journal of Clinical Gastroenterology</i> , 2005 , 39, S125-30	3	103
16	Utility of color Doppler ultrasonography predicting tips dysfunction. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2696-701	0.7	38
15	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. <i>British Journal of Haematology</i> , 2004 , 124, 329-35	4.5	19
14	Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. <i>Gastroenterology</i> , 2004 , 126, 469-75	13.3	386
13	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004 , 126, 749-55	13.3	208

12	Management of gastrointestinal bleeding in patients with cirrhosis of the liver. <i>Seminars in Hematology</i> , 2004 , 41, 8-12	4	19
11	Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. <i>Hepatology</i> , 2003 , 37, 172-81	11.2	110
10	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003 , 37, 378-84	11.2	68
9	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. <i>Hepatology</i> , 2003 , 37, 902-8	11.2	366
8	Current management of portal hypertension. <i>Journal of Hepatology</i> , 2003 , 38 Suppl 1, S54-68	13.4	188
7	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2003 , 39, 515-21	13.4	61
6	Novel approaches to treat portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17 Suppl 3, S232-41	4	3
5	Nitric oxide and portal hypertension. <i>Metabolic Brain Disease</i> , 2002 , 17, 311-24	3.9	25
4	Somatostatin and analogues in portal hypertension. <i>Hepatology</i> , 2002 , 35, 1305-12	11.2	66
3	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002 , 36, 1367-73	11.2	84
2	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. <i>Liver Transplantation</i> , 2001 , 7, 649-51	4.5	14
1	Selective arterial embolization for life threatening hemobilia after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Hepatology</i> , 2001 , 34, 174-6	13.4	8